

Chapter 2

Etiologies of Primary Ovarian Insufficiency

Nastaran Foyouzi, Lisa J. Green, and Sally A. Camper

Clinical Vignette

“I could not stop crying when my doctor told me I was in menopause! I was only 32 years old and married less than year ago! I wondered whether I had done anything wrong. Later I found out that my grandmother, mother and my aunt went through menopause when they were in their 30’s, but we had never talked about these things before. I never expected this would happen to me because everyone in my family has had several children. I wish I had known about this problem sooner. I really want to understand why this happened.”

Primary ovarian insufficiency (POI), formerly known as premature ovarian failure (POF), is defined as the cessation of ovarian function before the age of 40, considering 52.5 years old as an average age of menopause (51–53 years old) in the USA [1, 2]. POI can present with infertility and eventually progress to cessation of ovarian function, which is considered the end point of the disease [3]. There are many contributors to POI, including genetics, environmental exposures, autoimmunity, etc. In this chapter, we review the major known contributors to POI.

A basic understanding of ovarian follicle development and loss provides a foundation for understanding the diversity of processes that can affect ovarian reserve. During embryonic development in humans, germ cells initially appear in the genital

N. Foyouzi, MD • L.J. Green, MD, MPH

Division of Reproductive Endocrinology and Infertility, OB & GYN Department,
University of Michigan, L4100 Women’s Hospital, 1500 E. Medical Center Dr,
SPC5276, Ann Arbor, MI 48104, USA
e-mail: nfoyouzi@med.umich.edu; grlisa@med.umich.edu

S.A. Camper, PhD (✉)

Department of Human Genetics, James V. Neel Professor and Chair, 1241 E Catherine St.,
Ann Arbor, MI 48109-5618, USA

Department of Internal Medicine, James V. Neel Professor and Chair, 1241 E Catherine St.,
Ann Arbor, MI 48109-5618, USA
e-mail: scamper@umich.edu

ridge and migrate to the primitive ovary where they proliferate to more than 3.5 million by about 20 weeks of gestation. The majority of these follicles will be lost during fetal and postnatal life by atresia [4, 5]. Females begin their reproductive life at puberty with only about 300,000 follicles in their ovaries. During each ovulatory cycle about 10 or 20 follicles undergo a maturation process that results in the release of one mature oocyte [6]. In sum, about 400–500 follicles are released during cycles of ovulation that occur during the childbearing years. Eventually, when the number of reserved follicles reaches approximately 1000, cessation of menses, or menopause, occurs [4, 5].

A variety of pathogenic mechanisms lead to the development of POI. These can be divided into four major categories: a follicular migration defect early in embryogenesis; an initial decrease in the primordial follicle pool; accelerated follicular atresia; or altered maturation or recruitment of primordial follicles. The etiologies of POI are highly heterogeneous and include genetic, autoimmune, metabolic or enzyme defects, infectious, and iatrogenic factors. Taken together, these account for only 10 % of the cases and the remaining 90 % are idiopathic, or largely unknown [7].

Genetic Causes

The evidence for genetic causes of POI comes from cases of chromosome abnormalities such as Turner syndrome [8–10], familial cases of POI [11–16], and evidence that the timing of natural menopause between sisters, daughters, and mothers is heritable [14, 17–20]. The most common X chromosomal abnormality is Turner syndrome (TS) with an incidence of 1:2500. Turner syndrome results when only one normal X chromosome is present and the other X chromosome is either missing or structurally altered. In 80 % of the cases, the lost X chromosome is paternal in origin [21]. In some cases the affected woman is mosaic for a normal karyotype and monosomy X. The missing genetic material in classical TS affects ovarian follicular development and function. The ovary begins to develop normally, but ovarian follicles of TS patients degenerate rapidly during prenatal life, often leading to gonadal dysgenesis with streak ovaries [7, 22]. Almost all patients require hormone therapy to undergo puberty [23].

Trisomy X and partial X chromosome defects in the form of deletions, isochromosomes, and balanced X autosome translocations can cause POI [10]. A major goal is to identify the genes that are critical for normal ovarian function that are disrupted in these chromosomal abnormalities. TS patients who lack only a portion of one of the X chromosomes or have an autosomal translocation with an X chromosome are valuable for identifying these critical genes. Cytogenetic analysis of these patients reveals that reduced dosage of genes on both the long (q) and short (p) arms of the X chromosome contributes to POI [23–25]. Deletions of the short arm of the X chromosome usually result in primary amenorrhea, whereas deletions of the long arm of the X chromosome result in either primary or secondary ovarian insufficiency [26, 27]. The critical region for ovarian development and function on

Xq chromosome spans Xq13.3 to q27, but the specific genes in this region that contribute to the phenotype are not yet known [25, 28, 29]. The short stature associated with Turner's syndrome results from reduced dosage of genes on Xp, and *SHOX* is a contributing gene [9, 26, 30–33]. Some chromosomal abnormalities may not delete the critical genes but cause “position effects,” or epigenetic changes that affect gene expression [34].

Although many POI patients have genetic defects involving the X chromosome, an increasing number of studies have documented autosomal gene involvement in the etiology of POI [27, 35, 36]. Some familial forms of POI have autosomal dominant sex-limited transmission or X-linked inheritance with incomplete penetrance [16, 36–39]. Recently, molecular genetic investigations of women with POI and experiments in genetically engineered mice have led to the identification of several genes that are critical for follicle function and oogenesis, such as *BMP15*, *FOXL2*, *GDF9*, *NR5A1*, *NOBOX*, *LHR*, and *FSHR*. Only a small fraction of POI cases can be explained by mutations in these genes, and the molecular pathogenesis remains speculative [40–44]. Currently, none of these genes are accepted as clinical genetic markers for POI [45, 46]. Much more regarding the genetics of POI is discussed in other chapters.

FMR (Fragile X Mental Retardation) Gene

The *FMR1* gene has a clinically significant association with POI. The *FMR1* gene is located on the X chromosome (Xq27.3) and contains an expandable region composed of trinucleotide repeats of CGG in the 5'UTR [47–50]. Three allelic classes can be defined based on the number of CGG repeats. Normal alleles have 6–55 CGG repeats, premutated alleles have 55–200 CGG repeats, and a full mutation contains 200 or more CGG repeats [51–54]. In males, the consequence of the full mutation is fragile X syndrome, the most common inherited cause of mental retardation. However, 2–5 % of women with the premutation allele have a substantially increased risk of POI [55–57]. It has been estimated that the *FMR* premutation accounts for about 21 % of familial and 6 % of sporadic forms of POI cases. The mutant *FMR* allele is toxic, possibly because the mutant transcripts sequester CGG binding proteins that are important for RNA processing. The *FMR* protein (*FMRP*) is highly expressed in fetal germinal cells of the ovary, and the mutant allele leads to a decrease of the initial pool of oocytes and increased rate of follicular atresia [35, 50, 58, 59]. Nevertheless, in carriers of the premutation who are over the age of 50, the toxic effect of the *FMR* mRNA can cause a neurodegenerative disorder: fragile X tremor ataxia syndrome [60].

Patients with *FMR* premutation have an unusual inheritance pattern. Affected individuals always inherit the expanded repeat from their mothers, and premutation-carrying males always pass on premutation alleles to their children [61, 62]. Furthermore, affected full mutation males produce sperm with only premutation alleles [63], and although full mutation germ cells are present in developing male

fetuses, these are gradually replaced with premutation-bearing germ cells [64]. This could be due to a proliferation advantage of FMR) protein producing cells or to a selection against male germ cells with large trinucleotide repeat expansions [65]. However, in females, selection against germ cells with an expanded full mutation allele on the active X chromosome may reduce the germ cell pool, and expansion on the inactive X chromosome may allow passage of full mutation alleles to offspring [61].

The co-segregation of POI and premutations in some families and the lack of POI in other fragile X families suggest that ovarian function is adversely affected by only a subset of premutation alleles. This model could partially account for the discrepant results of the various association studies between POI and fragile X mutations as the various study groups may differ in the proportion of alleles that are associated with POI. Differences between the POI and non-POI premutation alleles could be due to linkage disequilibrium with a nearby POI-causing mutation or due to variations in the structure of the repeat itself, such as AGG interruption pattern or length of pure CGG tracts. Such changes may be responsible for subtle, but critical, changes in FMRP level. Other confounding factors could include modifying genes, perhaps also affecting FMRP levels, as well as the various genetic and environmental factors known to affect age at menopause. Whatever the mechanism of the association between *FMR1* and ovarian function, the challenges raised by the differing results in various populations reflect the complexity at work in this particular genotype–phenotype relationship.

Autoimmune Causes

Autoimmune disease accounts for approximately 4 % of POI cases [66]. The trigger for ovarian autoimmunity is unknown, but it might be due to abnormalities in self-recognition by the immune system, resulting in a loss of tolerance to some component of ovarian tissue, and ultimately ovarian tissue damage [13, 66, 67]. Animal studies suggest involvement of immune-regulatory regions outside the histocompatibility (H-2) locus on mouse chromosome 3 as an associated factor for ovarian damage [67–70]. In humans, HLA-DQB1*0301 and HLADQB1* 0603 are proposed as an associated factor with 3b-HSD autoimmunity (adrenal autoantibody) in POI subjects [71, 72].

Approximately 3 % of women with POI have an endocrine dysfunction known as autoimmune polyglandular syndrome (APS), types I and II [73]. The type I syndrome is a rare autosomal recessive disorder characterized by multiple organ-specific autoimmunities secondary to a variety of autoantibodies directed against key intracellular enzymes. Sixty percent of APS type I patients have POI. APS type II is an autosomal dominant disorder, and it is associated with gonadal failure in 4 % of patients [73, 74]. Adrenal insufficiency is a component of both APS types, and 2–10 % of POI cases show evidence of autoimmunity against the adrenal gland [67, 75–77]. In those cases where POI is associated with adrenal autoimmunity,

histological examination almost always confirms the presence of an autoimmune oophoritis in which follicles are infiltrated by lymphocytes, plasma cells, and macrophages that attack mainly steroid-producing cells and eventually result in follicular depletion [78, 79]. Lymphocytic infiltration is more prominent in mature follicles suggesting that production of the self-antigen may be gonadotropin dependent. The zona pellucida (ZP) is an important antigenic determinant of autoimmune POI that affects ZP function, which in turn affects follicular development leading to infertility in women with POI [75, 80]. Lymphocytic infiltration may also be present in the ovarian hilum, with an accumulation of lymphocytes around neural tissue. POI is more common with APS type I than with APS type II. It has been proposed that α -enolase may serve as a candidate target antigen in POI associated with polyglandular syndromes [80–85].

Several other autoimmune disorders have been associated with POI. Hypothyroidism is the most common. In this case, POI subjects will present with antithyroid antibodies and either clinical or subclinical hypothyroidism [74]. The other POI associated autoimmune alterations are parietal cell antibodies, acetylcholine receptor antibodies in myasthenia gravis, chronic candidiasis, idiopathic thrombocytopenic purpura, vitiligo, alopecia, autoimmune hemolytic anemia, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, Sjögren's syndrome, primary biliary cirrhosis, and insulin-dependent diabetes (2 %) [66, 74, 75, 86–89]. The risk for these diseases in women with POI is higher than in the general population, suggesting that there may be a still unknown autoimmune component involved [90, 91].

Enzyme Deficiency

POI is the most common long-term complication experienced by girls and women with classic galactosemia. Galactosemia is a rare autosomal recessive disorder due to a defect in galactose 1-phosphate uridylyltransferase (GALT) enzyme function [92, 93]. The prevalence of POI is 80–90 % in patients with galactosemia despite neonatal diagnosis and careful lifelong dietary restriction of galactose [94]. The cause of POI in classic galactosemia is not yet understood. The most common cause of classical galactosemia is the Q188R mutation, which is followed by the K285N in central European populations [95]. Several other mechanisms also have been proposed, like direct toxicity of metabolites (i.e., galactose-1-phosphate) on follicular structures during fetal life, altered gene expression, or aberrant function of hormones and receptors due to glycosylation abnormalities leading to biological inactivity [81, 94, 96, 97]. Histological findings are consistent with hypoplastic or streak ovaries [98, 99] and fewer follicles than expected for the patient's age to almost complete absence of follicles [100–103]. The few follicles present in the ovaries of classic galactosemia patients are mainly of the primordial type, and maturing follicles are rarely seen [104, 105]. Anecdotal studies in girls at very young prepubertal ages suggest that a normal pool of primordial follicles forms

early in life, but the follicles undergo very rapid atresia, causing a severe decline in the follicular pool and ovarian hypoplasia [101, 104, 106].

Studies in animal models also support a link between galactose metabolism and ovarian toxicity. For example, adult female rats fed a high galactose diet have diminished follicular development [107, 108]. Even prenatal exposure to galactose inhibits germ cell migration and can cause a reduction in oocyte pools [109, 110]. In contrast, the GALT knockout mice have normal fertility, even when challenged with a high galactose diet. The basis for this difference between mice and rat ovaries is unclear [111, 112].

Aberrant FSH function may occur due to abnormal glycosylation of the hormone in women with classic galactosemia. The glycosylation state of follicle-stimulating hormone (FSH) is directly linked to its bioactivity *in vivo*, as well as to its rate of clearance, potency, and receptor binding and activation; therefore, hypoglycosylated isoform of FSH may even act as an antagonist [113, 114].

Duarte galactosemia is a mild variant of galactose-1-P-uridy-lyltransferase (GALT) deficiency, characterized by the N314D mutation and additional intron and promoter sequence variations [95]. Patients with classic galactosemia have ≤ 1 % normal GALT activity in hemolysates, and patients with Duarte galactosemia have on average 25 % of the normal GALT enzyme activity levels [115–118]. The incidence of Duarte galactosemia in newborns is 10 times higher than classical galactosemia [117, 119, 120]. Whether girls or women with Duarte galactosemia are at increased risk for POI is not completely clear. Small studies of girls with Duarte galactosemia and heterozygous carriers for classic galactosemia, which would be expected to have 50 % the normal level of GALT, did not find any abnormalities in FSH, inhibin B, anti-Müllerian hormone (AMH), or sonographic antral follicle count [121, 122]. The mean age of menopause of classic galactosemia carriers is not different from normal controls. Larger studies are warranted to understand the impact of Duarte galactosemia on risk for POI.

Infectious Causes

The autoimmune assault of ovarian tissue can be triggered by various agents like viruses, bacteria, or self-ovarian antigens. The mumps and rubella viruses are well-known triggers of autoantibody production. Mumps oophoritis may cause POI with an incidence of 3–7 % in patients who contracted mumps during epidemic episodes [80, 81, 123]. However, the true incidence of post-oophoritis ovarian failure is unknown. Fortunately, a vast majority of affected women regain their ovarian function following recovery from the disease [124, 125]. There are also anecdotal reports of other viral and microbial infection followed by POI, such as tuberculosis, varicella, cytomegalovirus in immune-compromised patients, malaria, and shigella [7, 124, 126], but a cause and effect relationship has not been established and evidence is inconclusive [123–125].

Iatrogenic Causes

Environment and Lifestyle

Environmental factors can significantly affect ovarian function. There are numerous epidemiologic studies confirming the negative impact of cigarette smoking on natural age of menopause. Cigarette smoke is a complex mixture of alkaloids (nicotine), polycyclic aromatic hydrocarbons (PAHs), nitroso compounds, aromatic amines, and protein pyrolysates, which are reactive and carcinogenic [127]. Women who are current smokers have been found to enter menopause, on average, 1–2 years earlier than nonsmokers [128–130]. Current smokers also have decreased follicle density [131] compared to nonsmokers, and therefore, lower age-related AMH [132] and increased FSH levels [133]. It is thought that the negative effect of cigarette smoking is dose dependent. In one retrospective cohort study, 656 naturally postmenopausal women were found to have a declining mean age of menopause with increasing number of cigarettes smoked [134]. In another study of women aged 44–53 years, there was a trend toward declining of age of menopause when comparing nonsmokers to current $>1/2$ to 1 pack/day smokers [135]. The mechanism of these effects is unknown; however, there are multiple animal and in vitro studies that demonstrate the ovotoxicity of PAH [136–138] through inducing accelerated oocyte atresia, follicle depletion, or dysregulation of the hypothalamic–pituitary–ovarian axis [128, 136, 139–141]. PAH was found to bind the aromatic hydrocarbon receptor of oocytes and granulosa cells, activating transcription of the proapoptotic gene *Bax* and consequently exerting its toxicity effect by triggering female germ cell death [142–146]. Taken together, animal studies strongly support the correlation between smoking and early onset of menopause in women.

The effect of nutrition and other endocrine disruptors such as 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) or Bisphenol A (BPA) on sex hormone levels and reproductive span has been studied in animal models although large prospective studies in humans are lacking [147–149]. Caloric restriction, particularly during early childhood, decreases the age at natural menopause as evidenced by the famous 1944–1945 Dutch famine [150]. However, studies on dietary factors and age of menopause are conflicting and need further investigation.

The presence of seizures has been reported as a risk factor for developing POI in a small study. Klein et al. [151] reported 14 % incidence of POI in women with epilepsy, irrespective of antiepileptic medication. Nevertheless, due to the small sample size this association needs more investigation.

Radiation

It is estimated that approximately one in 50 women will have a diagnosis of cancer before the age of 40 [152], and with recent advances in success of childhood cancer treatments the prevalence of iatrogenic POI has been increased [153]. Numerous

clinical studies, reviews, and meta-analyses have examined the effects of anticancer treatments (i.e., radiation and chemotherapy) on female reproductive function. In general, these treatments frequently result in irreversible loss of ovarian function depending on the type and dose of radiation [154, 155]. Women who are exposed to total body irradiation or irradiation of the abdomen or pelvic area are more likely to suffer irreversible ovarian damage and amenorrhea than those exposed in other places [156–158]. Additionally, radiotherapy that has given in a fractionated protocol is safer than a single protocol with a higher exposure [159]. Although the median lethal dose (LD50) of primordial follicles has been reported to be between 2 and 6–18 Gray (Gy) [160, 161], it is estimated that as little as 2 Gy is able to cause loss of the half of human follicles [162]. At birth, the effective dose of fractionated radiotherapy at which POI ensures is 20.3 Gy; however, at 10 years the dose decreases to 18.4, at 20 years 16.5, and at 30 years 14.3 Gy [162, 163]. One study concluded that 26 % of women with total abdominal radiation for approximately 3.5 years developed POI by the age of 23 [164]. Patients who receive a stem cell transplant with total body irradiation are at the greatest risk of developing POI. Virtually 100 % of patients who undergo a marrow transplant with total body irradiation after age 10 will develop acute ovarian failure, whereas 50 % of girls who received total body irradiation before the age of 10 will suffer from acute loss of ovarian function [158]. Therefore, risk of ovarian failure is dependent on the age at exposure (younger girls or women are more resistant), the dose, whether or not the pelvic area is being exposed, and the fractionation of doses [162, 165, 166].

Chemotherapy

POI is an unfortunate sequel of cytotoxic chemotherapy [167]. The gonadotoxic effect of chemotherapy on ovarian function can be transient, with the most important predictive factors of ovarian damage being age, dose, type of chemotherapeutic agent, and the number of cycles/exposure [158, 168]. Higher doses and older age at treatment are both associated with greater damage [169, 170].

Of the various chemotherapeutic drug classes, alkylating agents are thought to be the most cytotoxic [156, 171]. Examples of commonly cited alkylating agents associated with POI include cyclophosphamide, melphalan, busulfan, chlorambucil, and nitrogen mustard [155, 158, 172–174]. After chemotherapy, patients have significantly decreased primordial follicle counts, and this effect is greater for those who were treated with alkylating agents [175]. In rodent models, cyclophosphamide causes a dose-dependent loss in primordial follicles even at doses as low as 20 mg/kg [176]. However, in a mouse model, a single dose of 200 mg/kg of cyclophosphamide results in an 87 % reduction in primordial follicle count 72 h after intraperitoneal administration [177, 178]. This effect is consistent with observations in humans [175]. The presence of amenorrhea soon after treatments also suggests a direct impact of chemotherapy on growing and antral follicles [158]. Byrne et al. have assessed the risk of early menopause in a cohort of 1067 childhood cancer patients

between 1945 and 1976 and found a 9.2-fold increased relative risk for those treated with alkylating agents and 27-fold for women who received a combination of abdomino-pelvic radiation and alkylating agents [179]. Additionally, adolescent cancer survivors who were diagnosed between the ages of 13–19 have four times greater risk of menopause than controls [179]. In addition to the effect of chemotherapy agents on primordial follicles, most regimens, regardless of whether they include an alkylating agent, may have detrimental effects on ovarian stromal function [175]. Therefore, considering static follicle counts as the sole measure of gonadotoxicity may lead to an underestimation of ovarian damage, as these stromal alterations may culminate in POI.

Surgery

Almost any pelvic surgery has the potential to damage the ovary by affecting its blood supply or causing inflammation in the area. Hysterectomy without bilateral oophorectomy, whether laparoscopic or abdominal, decreases ovarian reserve and causes a nearly twofold increased risk of POI [180–183]. While FSH levels in women with hysterectomies and controls provide compelling evidence to support the increased incidence of POI following hysterectomy, the mechanistic pathway is still unknown [183, 184].

Uterine artery embolization (UAE), an interventional technique used to manage various gynecological disorders, has the potential to cause POI by compromising the vascular supply to the ovary [185, 186]. In a randomized controlled trial of women undergoing either hysterectomy or UAE, both groups were found to have a significant increase in FSH compared to baseline and a significant reduction in AMH levels compared to the age expected levels at the end of the 24-month follow-up [186]. The effect of UAE on ovarian reserve has been found to be equal to that of hysterectomy and myomectomy [186–189]. POI can occur following surgery for bilateral endometriomas [190–192]. The frequency of this complication is estimated to be 2.4 %, but further confirmation is warranted. It is not known whether postsurgical ovarian dysfunction is attributable to the underlying clinical problem that prompted the cystectomy or endometrioma or whether surgery itself is a contributing factor. More studies are necessary to resolve this.

Conclusion

The etiology of POI is clearly heterogeneous and often largely unknown. The advances in genomic, environmental, and biomarker research will give us a better mechanistic understanding of the basic regulation of ovarian development and function as well as pathologic decline in the ovarian reserve. The future holds great promise for having a deeper understanding of the origins of POI.

References

1. Kato I, et al. Prospective study of factors influencing the onset of natural menopause. *J Clin Epidemiol*. 1998;51(12):1271–6.
2. Gold EB, et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. *Am J Epidemiol*. 2013;178(1):70–83.
3. Nelson LM. Clinical practice. Primary ovarian insufficiency. *N Engl J Med*. 2009;360(6):606–14.
4. Motta PM, Makabe S. Elimination of germ cells during differentiation of the human ovary: an electron microscopic study. *Eur J Obstet Gynecol Reprod Biol*. 1986;22(5-6):271–86.
5. Motta PM, Makabe S. Germ cells in the ovarian surface during fetal development in humans. A three-dimensional microanatomical study by scanning and transmission electron microscopy. *J Submicrosc Cytol*. 1986;18(2):271–90.
6. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. *Endocr Rev*. 2000;21(2):200–14.
7. Goswami D, Conway GS. Premature ovarian failure. *Hum Reprod Update*. 2005;11(4):391–410.
8. Zinn AR, Page DC, Fisher EM. Turner syndrome: the case of the missing sex chromosome. *Trends Genet*. 1993;9(3):90–3.
9. Zinn AR, et al. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. *Am J Hum Genet*. 1998;63(6):1757–66.
10. Zinn AR. The X chromosome and the ovary. *J Soc Gynecol Investig*. 2001;8(1 Suppl Proceedings):S34–6.
11. van Kasteren YM, et al. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? *Hum Reprod*. 1999;14(10):2455–9.
12. Starup J, Sele V. Premature ovarian failure. *Acta Obstet Gynecol Scand*. 1973;52(3):259–68.
13. Conway GS, et al. Characterization of idiopathic premature ovarian failure. *Fertil Steril*. 1996;65(2):337–41.
14. Torgerson DJ, Thomas RE, Reid DM. Mothers and daughters menopausal ages: is there a link? *Eur J Obstet Gynecol Reprod Biol*. 1997;74(1):63–6.
15. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. *Fertil Steril*. 1995;64(4):740–5.
16. Vegetti W, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. *Hum Reprod*. 1998;13(7):1796–800.
17. van Asselt KM, et al. Heritability of menopausal age in mothers and daughters. *Fertil Steril*. 2004;82(5):1348–51.
18. Janse F, et al. Similar phenotype characteristics comparing familial and sporadic premature ovarian failure. *Menopause*. 2010;17(4):758–65.
19. Murabito JM, et al. Heritability of age at natural menopause in the Framingham Heart Study. *J Clin Endocrinol Metab*. 2005;90(6):3427–30.
20. Murabito JM, et al. Genome-wide linkage analysis to age at natural menopause in a community-based sample: the Framingham Heart Study. *Fertil Steril*. 2005;84(6):1674–9.
21. Loughlin SA, et al. Analysis of the origin of Turner's syndrome using polymorphic DNA probes. *J Med Genet*. 1991;28(3):156–8.
22. Hughesdon PE. Ovarian pathology in primary amenorrhoea. *Proc R Soc Med*. 1970;63(3):294–7.
23. Sybert VP, McCauley E. Turner's syndrome. *N Engl J Med*. 2004;351(12):1227–38.
24. Lyon MF. The X inactivation centre and X chromosome imprinting. *Eur J Hum Genet*. 1994;2(4):255–61.
25. Zinn AR, Ross JL. Turner syndrome and haploinsufficiency. *Curr Opin Genet Dev*. 1998;8(3):322–7.
26. Goldman B, et al. Clinical and cytogenetic aspects of X-chromosome deletions. *Clin Genet*. 1982;21(1):36–52.

27. Simpson JL, Rajkovic A. Ovarian differentiation and gonadal failure. *Am J Med Genet.* 1999;89(4):186–200.
28. Trunca C, Therman E, Rosenwaks Z. The phenotypic effects of small, distal Xq deletions. *Hum Genet.* 1984;68(1):87–9.
29. Beke A, et al. Molecular cytogenetic analysis of Xq critical regions in premature ovarian failure. *Mol Cytogenet.* 2013;6(1):62.
30. Kalousek D, et al. Partial short arm deletions of the X chromosome and spontaneous pubertal development in girls with short stature. *J Pediatr.* 1979;94(6):891–4.
31. Jacobs PA. The role of chromosome abnormalities in reproductive failure. *Reprod Nutr Dev.* 1990; Suppl 1: 63s–74s.
32. Temtamy SA, et al. Karyotype/phenotype correlation in females with short stature. *Clin Genet.* 1992;41(3):147–51.
33. Ogata T, Matsuo N. Turner syndrome and female sex chromosome aberrations: deduction of the principal factors involved in the development of clinical features. *Hum Genet.* 1995;95(6):607–29.
34. Persani L, et al. Primary Ovarian Insufficiency: X chromosome defects and autoimmunity. *J Autoimmun.* 2009;33(1):35–41.
35. Cordts EB, et al. Genetic aspects of premature ovarian failure: a literature review. *Arch Gynecol Obstet.* 2011;283(3):635–43.
36. Christin-Maitre S, et al. Genes and premature ovarian failure. *Mol Cell Endocrinol.* 1998;145(1-2):75–80.
37. Coulam CB, Stringfellow S, Hoefnagel D. Evidence for a genetic factor in the etiology of premature ovarian failure. *Fertil Steril.* 1983;40(5):693–5.
38. Davis CJ, et al. Female sex preponderance for idiopathic familial premature ovarian failure suggests an X chromosome defect: opinion. *Hum Reprod.* 2000;15(11):2418–22.
39. Mattison DR, et al. Familial premature ovarian failure. *Am J Hum Genet.* 1984;36(6):1341–8.
40. Rossetti R, et al. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. *Hum Mutat.* 2009;30(5):804–10.
41. Laissue P, et al. Recent advances in the study of genes involved in non-syndromic premature ovarian failure. *Mol Cell Endocrinol.* 2008;282(1-2):101–11.
42. Skillern A, Rajkovic A. Recent developments in identifying genetic determinants of premature ovarian failure. *Sex Dev.* 2008;2(4-5):228–43.
43. Simpson JL. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. *Ann N Y Acad Sci.* 2008;1135:146–54.
44. Lourenco D, et al. Mutations in NR5A1 associated with ovarian insufficiency. *N Engl J Med.* 2009;360(12):1200–10.
45. Harris SE, et al. Identification of novel mutations in FOXL2 associated with premature ovarian failure. *Mol Hum Reprod.* 2002;8(8):729–33.
46. Lamberts SW, Uitterlinden AG. Genetic testing in clinical practice. *Annu Rev Med.* 2009;60:431–42.
47. Cronister A, et al. Mental impairment in cytogenetically positive fragile X females. *Am J Med Genet.* 1991;38(2-3):503–4.
48. Schwartz CE, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. *Am J Med Genet.* 1994;51(4):400–2.
49. Murray A, et al. Studies of FRAXA and FRAXE in women with premature ovarian failure. *J Med Genet.* 1998;35(8):637–40.
50. Martin JR, Arici A. Fragile X and reproduction. *Curr Opin Obstet Gynecol.* 2008;20(3):216–20.
51. Verkerk AJ, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell.* 1991;65(5):905–14.
52. Sutcliffe JS, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. *Hum Mol Genet.* 1992;1(6):397–400.

53. Feng Y, et al. Translational suppression by trinucleotide repeat expansion at FMR1. *Science*. 1995;268(5211):731–4.
54. Feng Y, et al. Quantitative comparison of FMR1 gene expression in normal and premutation alleles. *Am J Hum Genet*. 1995;56(1):106–13.
55. Wittenberger MD, et al. The FMR1 premutation and reproduction. *Fertil Steril*. 2007;87(3):456–65.
56. Conway GS, et al. Fragile X premutation screening in women with premature ovarian failure. *Hum Reprod*. 1998;13(5):1184–7.
57. Allingham-Hawkins DJ, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. *Am J Med Genet*. 1999;83(4):322–5.
58. Greco CM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). *Brain*. 2006;129(Pt 1):243–55.
59. Allen EG, et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. *Hum Reprod*. 2007;22(8):2142–52.
60. Hagerman RJ, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. *Am J Hum Genet*. 2004;74(5):1051–6.
61. Fu YH, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. *Cell*. 1991;67(6):1047–58.
62. Oberle I, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. *Science*. 1991;252(5009):1097–102.
63. Reyniers E, et al. The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm. *Nat Genet*. 1993;4(2):143–6.
64. Malter HE, et al. Characterization of the full fragile X syndrome mutation in fetal gametes. *Nat Genet*. 1997;15(2):165–9.
65. Kenneson A, Warren ST. The female and the fragile X reviewed. *Semin Reprod Med*. 2001;19(2):159–65.
66. Bakalov VK, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. *Fertil Steril*. 2005;84(4):958–65.
67. Nelson LM. Autoimmune ovarian failure: comparing the mouse model and the human disease. *J Soc Gynecol Investig*. 2001;8(1 Suppl Proceedings):S55–7.
68. Teuscher C, et al. Aod2, the locus controlling development of atrophy in neonatal thymectomy-induced autoimmune ovarian dysgenesis, co-localizes with Il2, Fgfb, and Idd3. *J Exp Med*. 1996;183(2):631–7.
69. Kojima A, Prehn RT. Genetic susceptibility to post-thymectomy autoimmune diseases in mice. *Immunogenetics*. 1981;14(1-2):15–27.
70. Nair S, Caspi RR, Nelson LM. Susceptibility to murine experimental autoimmune oophoritis is associated with genes outside the major histocompatibility complex (MHC). *Am J Reprod Immunol*. 1996;36(2):107–10.
71. Arif S, et al. Human leukocyte antigen-DQB1* genotypes encoding aspartate at position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure. *J Clin Endocrinol Metab*. 1999;84(3):1056–60.
72. Reimand K, et al. 3beta-hydroxysteroid dehydrogenase autoantibodies are rare in premature ovarian failure. *J Clin Endocrinol Metab*. 2000;85(6):2324–6.
73. Kauffman RP, Castracane VD. Premature ovarian failure associated with autoimmune polyglandular syndrome: pathophysiological mechanisms and future fertility. *J Womens Health (Larchmt)*. 2003;12(5):513–20.
74. Betterle C, et al. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. *Endocr Rev*. 2002;23(3):327–64.
75. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. *Endocr Rev*. 1997;18(1):107–34.
76. Bakalov VK, et al. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. *Hum Reprod*. 2002;17(8):2096–100.

77. Forges T, et al. Autoimmunity and antigenic targets in ovarian pathology. *Hum Reprod Update*. 2004;10(2):163–75.
78. Irvine WJ, et al. Immunological aspects of premature ovarian failure associated with idiopathic Addison's disease. *Lancet*. 1968;2(7574):883–7.
79. Dragojevic-Dikic S, et al. An immunological insight into premature ovarian failure (POF). *Autoimmun Rev*. 2010;9(11):771–4.
80. Sinha P, Kuruba N. Premature ovarian failure. *J Obstet Gynaecol*. 2007;27(1):16–9.
81. Nippita TA, Baber RJ. Premature ovarian failure: a review. *Climacteric*. 2007;10(1):11–22.
82. Kelkar RL, et al. Circulating auto-antibodies against the zona pellucida and thyroid microsomal antigen in women with premature ovarian failure. *J Reprod Immunol*. 2005;66(1):53–67.
83. Sundblad V, et al. Alpha-enolase: a novel autoantigen in patients with premature ovarian failure. *Clin Endocrinol (Oxf)*. 2006;65(6):745–51.
84. Tuohy VK, Altuntas CZ. Autoimmunity and premature ovarian failure. *Curr Opin Obstet Gynecol*. 2007;19(4):366–9.
85. Chen S, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. *J Clin Endocrinol Metab*. 1996;81(5):1871–6.
86. LaBarbera AR, et al. Autoimmune etiology in premature ovarian failure. *Am J Reprod Immunol Microbiol*. 1988;16(3):115–22.
87. Betterle C, et al. Premature ovarian failure: autoimmunity and natural history. *Clin Endocrinol (Oxf)*. 1993;39(1):35–43.
88. Greco CM, et al. Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. *Arch Neurol*. 2008;65(8):1114–6.
89. Coffey SM, et al. Expanded clinical phenotype of women with the FMR1 premutation. *Am J Med Genet A*. 2008;146A(8):1009–16.
90. Ebrahimi M, Akbari AF. Pathogenesis and causes of premature ovarian failure: an update. *Int J Fertil Steril*. 2011;5(2):54–65.
91. Kokcu A. Premature ovarian failure from current perspective. *Gynecol Endocrinol*. 2010;26(8):555–62.
92. Fraser IS, et al. Failure to identify heterozygotes for galactosaemia in women with premature ovarian failure. *Lancet*. 1987;2(8558):566.
93. Guerrero NV, et al. Risk factors for premature ovarian failure in females with galactosemia. *J Pediatr*. 2000;137(6):833–41.
94. Fridovich-Keil JL, et al. Ovarian function in girls and women with GALT-deficiency galactosemia. *J Inherit Metab Dis*. 2011;34(2):357–66.
95. Mlinar B, et al. Galactose-1-phosphate uridyl transferase gene mutations in women with premature ovarian failure. *Fertil Steril*. 2005;84(1):253–5.
96. Forges T, et al. Pathophysiology of impaired ovarian function in galactosaemia. *Hum Reprod Update*. 2006;12(5):573–84.
97. Forges T, Monnier-Barbarino P. [Premature ovarian failure in galactosaemia: pathophysiology and clinical management]. *Pathol Biol (Paris)*. 2003;51(1):47–56.
98. Schwarz HP, et al. Feminization in a galactosemic girl in the presence of hypergonadotropic hypogonadism. *Acta Endocrinol Suppl (Copenh)*. 1986;279:428–33.
99. Hoefnagel D, Wurster-Hill D, Child EL. Ovarian failure in galactosaemia. *Lancet*. 1979;2(8153):1197.
100. Rubio-Gozalbo ME, et al. Gonadal function in male and female patients with classic galactosemia. *Hum Reprod Update*. 2010;16(2):177–88.
101. Kaufman FR, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. *N Engl J Med*. 1981;304(17):994–8.
102. Morrow RJ, et al. Ovarian failure in a young woman with galactosaemia. *Ulster Med J*. 1985;54(2):218–20.
103. Beauvais P, Guilhaume A. Ovarian insufficiency in congenital galactosemia. *Presse Med*. 1984;13(44):2685–7.
104. Fraser IS, et al. Resistant ovary syndrome and premature ovarian failure in young women with galactosaemia. *Clin Reprod Fertil*. 1986;4(2):133–8.

105. Sauer MV, et al. Pregnancy after oocyte donation to a woman with ovarian failure and classical galactosemia. *Fertil Steril*. 1991;55(6):1197–9.
106. Levy HL, et al. Ovarian failure in galactosemia. *N Engl J Med*. 1984;310(1):50.
107. Liu G, et al. Dietary galactose inhibits GDF-9 mediated follicular development in the rat ovary. *Reprod Toxicol*. 2006;21(1):26–33.
108. Lai KW, et al. Inhibitor of apoptosis proteins and ovarian dysfunction in galactosemic rats. *Cell Tissue Res*. 2003;311(3):417–25.
109. Chen YT, et al. Reduction in oocyte number following prenatal exposure to a diet high in galactose. *Science*. 1981;214(4525):1145–7.
110. Bandyopadhyay S, et al. Prenatal exposure to high galactose adversely affects initial gonadal pool of germ cells in rats. *Hum Reprod*. 2003;18(2):276–82.
111. Leslie ND, et al. A mouse model of galactose-1-phosphate uridyl transferase deficiency. *Biochem Mol Med*. 1996;59(1):7–12.
112. Wehrli S, Reynolds R, Segal S. Evidence for function of UDP galactose pyrophosphorylase in mice with absent galactose-1-phosphate uridyltransferase. *Mol Genet Metab*. 2007;91(2):191–4.
113. Prestoz LL, et al. Altered follicle stimulating hormone isoforms in female galactosaemia patients. *Eur J Pediatr*. 1997;156(2):116–20.
114. Barrios-De-Tomasi J, et al. Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones. *Mol Cell Endocrinol*. 2002;186(2):189–98.
115. Donnell GN, et al. Duarte variant-galactosemia heterozygote. Repository identification No. GM-1996. *Cytogenet Cell Genet*. 1977;19(1):53–4.
116. Kaloud H, Sitzmann FC. Gene frequency of hereditary galactosemia with reference to the Duarte variant. *Z Kinderheilkd*. 1972;113(3):205–14.
117. Beutler E. Screening for galactosemia. Studies of the gene frequencies for galactosemia and the Duarte variant. *Isr J Med Sci*. 1973;9(9):1323–9.
118. Ng WG, Lee JS, Donnell GN. Transferase-deficiency galactosemia and the Duarte variant. *JAMA*. 1987;257(2):187–8.
119. Fernhoff PM. Duarte galactosemia: how sweet is it? *Clin Chem*. 2010;56(7):1045–6.
120. Ficicioglu C, et al. Monitoring of biochemical status in children with Duarte galactosemia: utility of galactose, galactitol, galactonate, and galactose 1-phosphate. *Clin Chem*. 2010;56(7):1177–82.
121. Badik JR, et al. Ovarian function in Duarte galactosemia. *Fertil Steril*. 2011;96(2):469–473e1.
122. Knauff EA, et al. Heterozygosity for the classical galactosemia mutation does not affect ovarian reserve and menopausal age. *Reprod Sci*. 2007;14(8):780–5.
123. Beck-Peccoz P, Persani L. Premature ovarian failure. *Orphanet J Rare Dis*. 2006;1:9.
124. Panay N, Kalu E. Management of premature ovarian failure. *Best Pract Res Clin Obstet Gynaecol*. 2009;23(1):129–40.
125. Meskhi A, Seif MW. Premature ovarian failure. *Curr Opin Obstet Gynecol*. 2006;18(4):418–26.
126. Fenichel P, et al. Prevalence, specificity and significance of ovarian antibodies during spontaneous premature ovarian failure. *Hum Reprod*. 1997;12(12):2623–8.
127. Stedman RL. The chemical composition of tobacco and tobacco smoke. *Chem Rev*. 1968;68(2):153–207.
128. Chmara-Pawlinska R, Szwed A. Cigarette smoking and the age of natural menopause in women in Poland. *Przegl Lek*. 2004;61(10):1003–5.
129. Rumianowski B, Rotter I, Brodowska A, Adler G, Kowalski J, Karakiewicz B, Laszczyńska M. Influence of selected reproductive factors and smoking on age at menopause. *Gesundheitswesen*. 2015 Jan 26. [Epub ahead of print] PMID: 25622211.
130. Gold EB, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol*. 2001;153(9):865–74.
131. Westhoff C, Murphy P, Heller D. Predictors of ovarian follicle number. *Fertil Steril*. 2000;74(4):624–8.

132. Dolleman M, et al. Reproductive and lifestyle determinants of anti-Mullerian hormone in a large population-based study. *J Clin Endocrinol Metab.* 2013;98(5):2106–15.
133. Kinney A, et al. Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. *Hum Reprod.* 2007;22(4):1175–85.
134. Kaufman DW, et al. Cigarette smoking and age at natural menopause. *Am J Public Health.* 1980;70(4):420–2.
135. Jick H, Porter J. Relation between smoking and age of natural menopause. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. *Lancet.* 1977;1(8026):1354–5.
136. Sobinoff AP, et al. Jumping the gun: smoking constituent BaP causes premature primordial follicle activation and impairs oocyte fusibility through oxidative stress. *Toxicol Appl Pharmacol.* 2012;260(1):70–80.
137. Borman SM, et al. Ovotoxicity in female Fischer rats and B6 mice induced by low-dose exposure to three polycyclic aromatic hydrocarbons: comparison through calculation of an ovotoxic index. *Toxicol Appl Pharmacol.* 2000;167(3):191–8.
138. Pru JK, et al. Induction of proapoptotic gene expression and recruitment of p53 herald ovarian follicle loss caused by polycyclic aromatic hydrocarbons. *Reprod Sci.* 2009;16(4):347–56.
139. Springer LN, et al. Involvement of apoptosis in 4-vinylcyclohexene diepoxide-induced ovotoxicity in rats. *Toxicol Appl Pharmacol.* 1996;139(2):394–401.
140. Tziomalos K, Charsoulis F. Endocrine effects of tobacco smoking. *Clin Endocrinol (Oxf).* 2004;61(6):664–74.
141. Sobinoff AP, et al. Scrambled and fried: cigarette smoke exposure causes antral follicle destruction and oocyte dysfunction through oxidative stress. *Toxicol Appl Pharmacol.* 2013;271(2):156–67.
142. Matikainen T, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. *Nat Genet.* 2001;28(4):355–60.
143. Tuttle AM, Stampfli M, Foster WG. Cigarette smoke causes follicle loss in mice ovaries at concentrations representative of human exposure. *Hum Reprod.* 2009;24(6):1452–9.
144. Weitzman GA, et al. Morphometric assessment of the murine ovarian toxicity of 7,12-dimethylbenz(a)anthracene. *Reprod Toxicol.* 1992;6(2):137–41.
145. Neal MS, et al. Aryl hydrocarbon receptor antagonists attenuate the deleterious effects of benzo[a]pyrene on isolated rat follicle development. *Reprod Biomed Online.* 2010;21(1):100–8.
146. Sadeu JC, Foster WG. Cigarette smoke condensate exposure delays follicular development and function in a stage-dependent manner. *Fertil Steril.* 2011;95(7):2410–7.
147. Sapre S, Thakur R. Lifestyle and dietary factors determine age at natural menopause. *J Midlife Health.* 2014;5(1):3–5.
148. Mark-Kappeler CJ, Hoyer PB, Devine PJ. Xenobiotic effects on ovarian preantral follicles. *Biol Reprod.* 2011;85(5):871–83.
149. Gregoraszcuk EL, Ptak A. Endocrine-disrupting chemicals: some actions of pops on female reproduction. *Int J Endocrinol.* 2013;2013:828532.
150. Elias SG, et al. Caloric restriction reduces age at menopause: the effect of the 1944-1945 Dutch famine. *Menopause.* 2003;10(5):399–405.
151. Klein P, Serje A, Pezzullo JC. Premature ovarian failure in women with epilepsy. *Epilepsia.* 2001;42(12):1584–9.
152. Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. *Cancer Manag Res.* 2014;6:105–17.
153. Panay N, Fenton A. Premature ovarian failure: a growing concern. *Climacteric.* 2008;11(1):1–3.
154. Byrne J. Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. *Teratology.* 1999;59(4):210–5.
155. Koyama H, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. *Cancer.* 1977;39(4):1403–9.

156. Chemaitilly W, et al. Acute ovarian failure in the childhood cancer survivor study. *J Clin Endocrinol Metab.* 2006;91(5):1723–8.
157. Sklar CA, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst.* 2006;98(13):890–6.
158. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. *J Natl Cancer Inst Monogr.* 2005;34:25–7.
159. Thibaud E, et al. Ovarian function after bone marrow transplantation during childhood. *Bone Marrow Transplant.* 1998;21(3):287–90.
160. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. *Hum Reprod.* 2003;18(1):117–21.
161. Burke PJ. Human oocyte radiosensitivity. *Radiol Technol.* 2004;75(6):419–24.
162. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. *Hum Reprod Update.* 2001;7(6):535–43.
163. Wallace WH, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. *Int J Radiat Oncol Biol Phys.* 2005;62(3):738–44.
164. de Moraes-Ruehsen M, Jones GS. Premature ovarian failure. *Fertil Steril.* 1967;18(4):440–61.
165. Green DM, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. *J Clin Oncol.* 2009;27(16):2677–85.
166. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? *Lancet Oncol.* 2005;6(4):209–18.
167. Cohen LE. Cancer treatment and the ovary: the effects of chemotherapy and radiation. *Ann N Y Acad Sci.* 2008;1135:123–5.
168. Chapman RM. Gonadal injury resulting from chemotherapy. *Am J Ind Med.* 1983;4(1-2):149–61.
169. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. *Am J Epidemiol.* 1999;150(3):245–54.
170. Larsen EC, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. *J Clin Endocrinol Metab.* 2003;88(11):5307–14.
171. Meirow D. Reproduction post-chemotherapy in young cancer patients. *Mol Cell Endocrinol.* 2000;169(1-2):123–31.
172. Schilsky RL, et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. *Ann Intern Med.* 1980;93(1):109–14.
173. Kulkarni SS, et al. Gonadal function following ABVD therapy for Hodgkin's disease. *Am J Clin Oncol.* 1997;20(4):354–7.
174. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. *Endocrinol Metab Clin North Am.* 1998;27(4):927–43.
175. Oktay O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. *Cancer.* 2007;110(10):2222–9.
176. Meirow D, et al. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. *Hum Reprod.* 1999;14(7):1903–7.
177. Plowchalk DR, Mattison DR. Phosphoramidate mustard is responsible for the ovarian toxicity of cyclophosphamide. *Toxicol Appl Pharmacol.* 1991;107(3):472–81.
178. Sato M, et al. Collaborative work on evaluation of ovarian toxicity. 7) Effects of 2- or 4- week repeated dose studies and fertility study of cyclophosphamide in female rats. *J Toxicol Sci.* 2009;34 Suppl 1:SP83–9.
179. Byrne J, et al. Early menopause in long-term survivors of cancer during adolescence. *Am J Obstet Gynecol.* 1992;166(3):788–93.
180. Yuan H, et al. Comparison of the effect of laparoscopic supracervical and total hysterectomy for uterine fibroids on ovarian reserve by assessing serum anti-Mullerian hormone levels: a prospective cohort study. *J Minim Invasive Gynecol.* 2015;22(4):637–41.

181. Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. *Fertil Steril*. 1987;47(1):94–100.
182. Wang HY, et al. Comparison of serum anti-Mullerian hormone levels following hysterectomy and myomectomy for benign gynaecological conditions. *Eur J Obstet Gynecol Reprod Biol*. 2013;171(2):368–71.
183. Moorman PG, et al. Effect of hysterectomy with ovarian preservation on ovarian function. *Obstet Gynecol*. 2011;118(6):1271–9.
184. Farquhar CM, et al. The association of hysterectomy and menopause: a prospective cohort study. *BJOG*. 2005;112(7):956–62.
185. Amato P, Roberts AC. Transient ovarian failure: a complication of uterine artery embolization. *Fertil Steril*. 2001;75(2):438–9.
186. Hehenkamp WJ, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. *Hum Reprod*. 2007;22(7):1996–2005.
187. Kaump GR, Spies JB. The impact of uterine artery embolization on ovarian function. *J Vasc Interv Radiol*. 2013;24(4):459–67.
188. Rashid S, et al. The effects of uterine artery embolisation and surgical treatment on ovarian function in women with uterine fibroids. *BJOG*. 2010;117(8):985–9.
189. Disu S, Kalu E. The effects of uterine artery embolisation and surgical treatment on ovarian function in women with uterine fibroids. *BJOG*. 2010;117(13):1663. author reply 1663–4.
190. Busacca M, et al. Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. *Am J Obstet Gynecol*. 2006;195(2):421–5.
191. Di Prospero F, Micucci G. Is operative laparoscopy safe in ovarian endometriosis? *Reprod Biomed Online*. 2009;18(2):167.
192. Coccia ME, et al. Ovarian surgery for bilateral endometriomas influences age at menopause. *Hum Reprod*. 2011;26(11):3000–7.

Primary Ovarian Insufficiency

A Clinical Guide to Early Menopause

Santoro, N.F.; Cooper, A.R. (Eds.)

2016, X, 207 p. 7 illus., 3 illus. in color., Hardcover

ISBN: 978-3-319-22490-9